Last reviewed 2026-04-19 · How we verify
Home › Drugs › Hanlim Pharm. Co., Ltd. › Cohort 3: HL217 Ophthalmic Solution QID Cohort 3: HL217 Ophthalmic Solution QID
At a glance
Generic name Cohort 3: HL217 Ophthalmic Solution QID Also known as 3mg/mL Sponsor Hanlim Pharm. Co., Ltd. Modality Small molecule Phase Phase 1
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/cohort-3-hl217-ophthalmic-solution-qid · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.